Nothing more endocrine than pondering over something so long that it doesn't matter any more! Well done!

I take it you are taking more time over your D&E application???

The advances in hypopara management keep coming!

I really wish I could! That would be some paper. I haven't seen any convincing data either way. I worry a RCT would be impossible.

Can you provide a plot with mortality directly attributable to hyponatraemia?

The slow-correcting heart failure patient will have higher mortality and a longer inpatient stay compared to the rapid-correcting patient with alcohol dependence and suppressed AVP. Their risks of ODS are not equivalent.

The omission of hypertonic saline strategies or hyponatraemia aetiologies limits it's utility. Not planning on changing my practice based on this paper having seen ODS first hand in rapid correctors.

Only a single dose was administered - could a further dose at 6 months and/or BTM monitoring have mitigated the BMD loss?